See more : PepsiCo, Inc. (PEP.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Probi AB (publ) (PBBIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Probi AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- UGRO Capital Limited (UGROCAP.NS) Income Statement Analysis – Financial Results
- Sydinvest Morningstar Global Markets Sustainability Leaders KL (SYIMSTARSULIKL.CO) Income Statement Analysis – Financial Results
- Northern Sphere Mining Corp. (NSMCF) Income Statement Analysis – Financial Results
- CF Bankshares Inc. (CFBK) Income Statement Analysis – Financial Results
- Allianz SE (ALV.DE) Income Statement Analysis – Financial Results
Probi AB (publ) (PBBIF)
About Probi AB (publ)
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 61.95M | 59.05M | 72.47M | 87.33M | 66.89M |
| Cost of Revenue | 40.41M | 34.65M | 40.76M | 49.58M | 35.74M |
| Gross Profit | 21.55M | 24.39M | 31.71M | 37.74M | 31.16M |
| Gross Profit Ratio | 34.78% | 41.32% | 43.76% | 43.22% | 46.57% |
| Research & Development | 4.42M | 3.95M | 4.39M | 5.18M | 4.01M |
| General & Administrative | 58.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 113.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.11M | 15.64M | 15.48M | 17.55M | 15.45M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -17.20K |
| Operating Expenses | 20.62M | 19.60M | 19.87M | 22.73M | 19.48M |
| Cost & Expenses | 60.84M | 54.25M | 60.62M | 72.31M | 55.21M |
| Interest Income | 794.34K | 162.83K | 16.96K | 29.35K | 152.01K |
| Interest Expense | 200.06K | 237.99K | 207.21K | 258.51K | 440.44K |
| Depreciation & Amortization | 9.50M | 7.30M | 6.93M | 7.73M | 6.99M |
| EBITDA | 11.41M | 12.50M | 18.97M | 22.61M | 19.11M |
| EBITDA Ratio | 18.42% | 20.49% | 25.91% | 26.05% | 27.91% |
| Operating Income | 11.32M | 4.80M | 11.84M | 15.01M | 11.68M |
| Operating Income Ratio | 18.27% | 8.13% | 16.34% | 17.19% | 17.46% |
| Total Other Income/Expenses | -9.60M | 164.45K | -12.33K | -391.84K | 2.67K |
| Income Before Tax | 1.72M | 4.96M | 11.83M | 14.62M | 11.68M |
| Income Before Tax Ratio | 2.77% | 8.41% | 16.32% | 16.74% | 17.46% |
| Income Tax Expense | 563.00K | 1.08M | 2.67M | 3.34M | 2.51M |
| Net Income | 1.66M | 3.88M | 9.15M | 11.29M | 9.17M |
| Net Income Ratio | 2.68% | 6.57% | 12.63% | 12.92% | 13.72% |
| EPS | 0.15 | 0.34 | 0.80 | 0.99 | 0.81 |
| EPS Diluted | 0.15 | 0.34 | 0.80 | 0.99 | 0.81 |
| Weighted Avg Shares Out | 11.39M | 11.39M | 11.39M | 11.39M | 11.39M |
| Weighted Avg Shares Out (Dil) | 11.39M | 11.39M | 11.39M | 11.39M | 11.39M |
Source: https://incomestatements.info
Category: Stock Reports